

INSTITUTIONAL BIOSAFETY COMMITTEE MINUTES

August 12th, 2025

Via Zoom

10:04am – 12:22pm

MEMBERS' PRESENT

1. Dr. Amy Sater Chairperson
2. Ms. Lisa Benford
3. Dr. Jason Eriksen
4. Dr. William Widger
5. Dr. David Brammer
6. Ms. Cris Milligan
7. Dr. Vivien Coulson-Thomas
8. Dr. Khan Abdul
9. Ms. Amberly Ross
10. Ms. Marian Downing
11. Mr. Andrew Saldana
12. Mr. Vicente Zuno

MEMBERS ABSENT

1. Dr. Laura Gutierrez
2. Mr. Steven I. Burns
3. Dr. Rachel Gamble

OTHER PRESENT

1. Dr. Zhen Fu
2. Mr. John McNeely
3. Mr. Keel Curtis
4. Ms. Daniela Cobas
5. Ms. Victoria Vaughn

MEETING AGENDA

- **Call Meeting to Order: 10:05am**
- **Review and Approval of May 16th, 2025, Meeting Minutes:** Unanimously approved.
 - a. FOR = 12
 - b. AGAINST = 0
 - c. ABSTENTIONS = 0
- **New NIH Requirements:** Presentation of the UH Office of General Counsel's IBC Meeting Records Memorandum

- **Introduction of Biological Safety Specialist**
- **IBC outcome determinations**
 - a. Approved
 - b. Approved with Modifications
 - c. Approved back to Subcommittee for Review
 - d. Withhold Approval, back to Full Committee

PROTOCOL REQUESTS FOR APPROVAL:

<p><u>Committee Determination</u></p> <p>Approved with Modifications</p> <p>FOR = 12 AGAINST = 0 ABSTENTIONS = 0</p>	<p><u>(Application Number:800) -BL2-007-25: Studies on Interactions Between Macrophages and Cancer Cells for Immunotherapy</u></p>
<p>NIH Guidelines:</p>	<p>III-F-4</p>
<p>Biosafety Level</p>	<p>2</p>
<p><u>Committee Determination</u></p> <p>Approved with Modification</p> <p>FOR = 12 AGAINST = 0 ABSTENTIONS = 0</p>	<p><u>(Application Number:820) -BL1-010-25: Plant Genetic Engineering for Nutrient Transport and Improved Biomass</u></p>
<p>NIH Guidelines:</p>	<p>III-E-2-a</p>
<p>Biosafety Level:</p>	<p>1</p>
<p><u>Committee Determination</u></p> <p>Approved back to Subcommittee for Review</p> <p>FOR = 12 AGAINST = 0 ABSTENTIONS = 0</p>	<p><u>(Application Number:827) -BL2-013-25: 3D Bioprinting of Hydrogels with Mammalian Cells and Bacteria</u></p>
<p>NIH Guidelines:</p>	<p>III-E-2-a</p>
<p>Biosafety Level:</p>	<p>2</p>

<u>Committee Determination</u> Approved with Modification FOR = 12 AGAINST = 0 ABSTENTIONS = 0	<u>(Application Number:787)-BL2R25-005-14: Biomarker Discovery and Drug Delivery Systems</u>
NIH Guidelines:	III-D-1-a
Biosafety Level:	2
<u>Committee Determination</u> Approved with Modifications FOR = 12 AGAINST = 0 ABSTENTIONS = 1	<u>(Application Number:814)-BL1R25-013-14: Isolation, Characterization and Cloning of an Actinobacterium Killing Factor from Tersicoccus Phoenixis.</u>
NIH Guidelines:	III-E-1
Biosafety Level	1

BSO APPROVED AMENDMENTS

1.Application798:BL2-002-22: Cellular Assays

The following amendments were approved:

- Addition of personnel
- Removal of personnel
- Addition of a cell line
-

2.Application:796:BL2-008-21: Electrical Synapse and Vision Restoration Research

The following amendments were approved:

- Addition of vectors: XX2 and pAdDeltaF6 to JOB 040825 (lines 50 and 51 on excel)
- Addition of DNA inserts: Bongwoori-Pos6, 7M8 cap and Rep, and E4, E2a and VA to ‘DNA inserts JOB-040825’(line 67, line 111, line 112 on excel sheet)
- Addition to General Description and Where Safety Risks Could Occur in reference to AAV
- Addition of laboratory locations: 3301D and 3301E

3.Application:816:BL2-011-24: Roles of BAF60a and BAF60c in Vascular Cells and Cardiovascular Diseases in Mice.

The following amendments were approved:

- Addition of personnel

4.Application:472:HPR-CASG17-12: Evaluating Sex Hormone and Cardiovascular Risk Factors for Chronic Disease (formally known as Collection of Capillary Blood Samples During Biomechanical Evaluations). The following

The following amendments were approved:

- Addition of personnel
- Addition of experimental procedures performed and sample volume change
- Addition of IRB approval number

5.Application:819:BL2-008-22: Cell-based Studies aimed at Determining the Efficiency of Covalent Anakinra at Inhibiting IL1 Receptor and Comparing this Efficiency with the FDA Approved Drug Anakinra.

The following amendments were approved:

- Addition of cell line-LNCaP: ARF876L
- Addition of vendor-Cancer Tools

6.Application:812:BL2-R24-008-18: Development of PSMA-CAR-NK and CAR-T Cell Therapy for Metastatic Prostate Cancer Treatment

The following amendments were approved:

- Addition and removal of personnel
- Addition of DNA inserts-CARM1 sgRNA and CARM1 cDNA

OTHER BUSINESS as PRESENTED-None

ADJOURNMENT: 12:22pm